Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02951026 · ClinicalTrials.gov registry record
An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis
A clinical trial, sponsored by Biosplice Therapeutics.
- Completed
- Registry status
- 703
- Enrollment target
NCT02951026 is a clinical trial that has completed, run by Biosplice Therapeutics. The registered enrollment target is 703 participants.
The verdict
NCT02951026 has completed, sponsored by Biosplice Therapeutics.
- COMPLETED
- Registry status
- 703 participants
- Enrollment target
Study Summary
This long-term extension study is designed to monitor the long-term safety, tolerability, and efficacy of treatment of SM04690 or placebo previously injected in the target knee joints of subjects with moderately to severely symptomatic osteoarthritis (OA) from a Samumed-sponsored SM04690-OA phase 2 or phase 3 study. No additional SM04690 or placebo therapy will be administered in this study.
Interventions
- OTHER Not applicable (no therapy is administered as part of this study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 703 participants |
| Start Date | 2016-09-19 |
| Est. Completion | 2019-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02951026
The ClinicalTrials.gov registry entry for NCT02951026 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 703 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Not applicable (no therapy is administered as part of this study) is the first listed.
NCT02951026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02951026 about?
NCT02951026 is a clinical study titled "An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis". This long-term extension study is designed to monitor the long-term safety, tolerability, and efficacy of treatment of SM04690 or placebo previously injected in the target knee joints of subjects with moderately to severely symptomatic osteoarthritis (OA) from a Samumed-sponsored SM04690-OA phase 2 ...
What is the current status of trial NCT02951026?
This trial is currently completed. The enrollment target is 703 participants. The study started on 2016-09-19. Estimated completion is 2019-10-31.
What interventions are being tested in trial NCT02951026?
The interventions under investigation include: Not applicable (no therapy is administered as part of this study) (OTHER).
Who is sponsoring clinical trial NCT02951026?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.